Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance
Authors:
- 16 July 2021
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 24 (6) , 1264-1277
Abstract
Background The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs. Organoid technology, a novel 3D cell culture system, allows harboring of patient-derived cancer cells containing abundant CSCs using niche factors in a dish. Methods In this study, we established L-OHP-resistant gastric cancer organoids (GCOs) and evaluated their gene expression profile using microarray analysis. We validated the upregulated genes in the L-OHP-resistant GCOs compared to their parental GCOs to find a gene responsible for L-OHP resistance by qRT-PCR, immunohistochemistry, in vitro, and in vivo experiments. Results We found myoferlin (MYOF) to be a candidate gene through microarray analysis. The results from cell viability assays and qRT-PCR showed that high expression of MYOF correlated significantly with the IC50 of L-OHP in GCOs. Immunohistochemistry of MYOF in GC tissue samples revealed that high expression of MYOF was significantly associated with poor prognosis, T grade, N grade, and lymphatic invasion, and showed MYOF to be an independent prognostic indicator, especially in the GC patients treated with platinum-based chemotherapy. The knockdown of MYOF repressed L-OHP resistance, cell growth, stem cell features, migration, invasion, and in vivo tumor growth. Conclusions Our results suggest that MYOF is highly involved in L-OHP resistance and tumor progression in GC. MYOF could be a promising biomarker and therapeutic target for L-OHP-resistant GC cases.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP15H04713, JP16K08691, JP18K07017, JP19H04443)
This publication has 32 references indexed in Scilit:
- Cancer drug resistance: an evolving paradigmNature Reviews Cancer, 2013
- Myoferlin Is a Key Regulator of EGFR Activity in Breast CancerCancer Research, 2013
- Liver–intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancerCancer Science, 2012
- Japanese classification of gastric carcinoma: 3rd English editionGastric Cancer, 2011
- Myoferlin regulation by NFAT in muscle injury, regeneration and repairJournal of Cell Science, 2010
- Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatinBiochemical Pharmacology, 2010
- Myoferlin is critical for endocytosis in endothelial cellsAmerican Journal of Physiology-Cell Physiology, 2009
- Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal nicheNature, 2009
- The Endocytic Recycling Protein EHD2 Interacts with Myoferlin to Regulate Myoblast FusionJournal of Biological Chemistry, 2008
- Normal myoblast fusion requires myoferlinDevelopment, 2005